Skip to main content
NovartisPro UAE

Main navigation (Don Not Delete)

    Menu
  • Products
    • Cardio – Renal – Metabolic
      • ENTRESTO® (Sacubitril / Valsartan)
      • LEQVIO® (Inclisiran)
    • Hematology
      • SCEMBLIX™ (asciminib)
    • Neurology
      • KESIMPTA™
Login
What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
2022 AHA/ACC/HFSA Heart Failure Guidelines
Read more about 2022 AHA/ACC/HFSA Heart Failure Guidelines
  • Print
  • PDF
Safety and Tolerability
Read more about Safety and Tolerability
  • Print
  • PDF
HFpEF with LVEF <60%
Read more about HFpEF with LVEF
  • Print
  • PDF
How Can ENTRESTO® Benefit HFrEF Patients
Read more about How Can ENTRESTO® Benefit HFrEF Patients
  • Print
  • PDF
Initiation and Titration
Read more about Initiation and Titration
  • Print
  • PDF
ENTRESTO® (Sacubitril / Valsartan)
Read more about ENTRESTO® (Sacubitril / Valsartan)
  • Print
  • PDF
Scemblix - Initiation and Dosing
Read more about Scemblix - Initiation and Dosing
  • Print
  • PDF
Scemblix-Safety
Read more about Scemblix-Safety
  • Print
  • PDF
Scemblix-Efficacy
Read more about Scemblix-Efficacy
  • Print
  • PDF
Scemblix-MOA (STAMP)
Read more about Scemblix-MOA (STAMP)
  • Print
  • PDF

Pagination

  • Page 1
  • Next page ››
Subscribe to Commercial

Novartis UAE

 

This site is intended for Healthcare Professionals only. 
Adverse Event Reporting
For Adverse event reporting to UAE EDE, please contact:
Email: [email protected]
website : Services | Ministry of Health and Prevention - United Arab Emirates
For any adverse events in Abu Dhabi, please report it to
Pharmacovigilance & Drugs Education [email protected]

To Report adverse events to Novartis:
Email to [email protected] or
Report online by visiting  https://www.report.novartis.com/
©2025 Novartis Middle East FZE

Helpful links

 

Terms of Use

Privacy Policy

Website Privacy Policy

Site Map

© 2025 Novartis